The purpose of this study is to test whether or not a medication called nabilone, which is a synthetic (non-natural) medication derived from cannabis, compared to placebo improves symptoms of itch in hemodialysis as measured by visual analog scales.
Who can participate
Age range25 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age\>25 years
✓. In-center or home hemodialysis at least two times weekly or peritoneal dialysis at least once daily for \>90 days
✓. Generalized uremic pruritus with a mean worst VAS\>40mm over the previous week (with at least 5/7 patient diary days completed)
✓. ALT less or equal to 3x upper limit of normal and bilirubin less than or equal to 2x upper limit of normal in the last 90 days
✓. Able to provide informed consent and complete patient reported outcome measurements without a language barrier or cognitive impairment
Exclusion criteria
✕. Etiology of pruritus (in the opinion of the treating physician) thought to be secondary to primary dermatologic condition, liver disease, hematologic malignancy or allergy
✕. Use of recreational or medical cannabis in the last 4 weeks (THC, CBD, nabilone, Sativex, Epidiolex)
✕. Women of childbearing potential as assessed by their clinician regardless of abstinence from sex or the use of contraception
✕. Planned kidney transplantation, travel or relocation in the next 3 months
✕. Unstable psychiatric illness (the presence of a lifetime diagnosis of a psychotic disorder, bipolar disorder, substance use disorder or current suicidal ideation)
✕. Symptomatic hypotension in the last 2 weeks defined as a systolic blood pressure (SBP) less than 90mmHg during or in between dialysis requiring an intervention (i.e. administration of crystalloid or colloid, termination of dialysis, change in pharmacologic therapy such as withdrawal of anti-hypertensive therapy or initiation/titration of midodrine, increase in dry weight)
What they're measuring
1
Change from baseline in worst uremic pruritis severity rating between treatment arms relative to MID
Timeframe: Measured at study baseline and weeks 1,2,3,4,5,6,7,8,9,10